Register for our free email digests:
Division of Pfizer Inc.
Latest From Redvax GMBH
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
Pfizer sees long-term growth potential in vaccines, fueled by new products targeted to patients across their life, from unborn children to seniors, including a portfolio of vaccines targeted to pregnant women and therapeutic cancer vaccines.
The company envisions maternal immunization as a new prong in its strategy to protect a full spectrum of people from disease through vaccinations, ranging from unborn children to senior citizens.
A year after its failed takeover bid for AstraZeneca, Pfizer Inc. continues to face questions about whether it will pursue another large-scale merger, and how it is preparing for a potential spin off.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
- Christian Schaub, Managing Dir.
- Contact Info
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.